|Bid||0.00 x 1300|
|Ask||0.00 x 3000|
|Day's Range||65.40 - 66.91|
|52 Week Range||61.05 - 78.38|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||30.47|
|Earnings Date||Jan 31, 2019|
|Forward Dividend & Yield||0.76 (1.20%)|
|1y Target Est||73.27|
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
Baxter International’s (BAX) net interest expense decreased from $14.0 million in the third quarter of 2017 to $11.0 million in the third quarter. The company’s net other income increased from $4.0 million in the third quarter of 2017 to $32.0 million in the third quarter. While the company incurred an income tax expense of $42.0 million in the third quarter of 2017, it received an income tax benefit of $138.0 million in the third quarter.
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, revealed its Peri-Strips Dry with Veritas (PSDV) Circular Staple Line Reinforcement with Secure Grip technology, the latest evolution in a product portfolio that has more than 20 years of proven clinical use in surgical buttressing and soft tissue repair. PSDV Circular is being showcased alongside the company’s comprehensive Advanced Surgery portfolio at the 2018 American Society for Metabolic and Bariatric Society (ASMBS) – Obesity Week meeting this week.
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
Baxter International Inc. said Tuesday its board has approved a $2 billion increase to its share buyback authorization, bringing the total available to $3.4 billion. The medical products company's shares were up 1.1% premarket, but have fallen about 5% in 2018, while the S&P 500 has gained 2%.
Baxter International Inc. (BAX), a leading global medical products company, announced today a quarterly cash dividend and an expanded authorization for its share repurchase program. Baxter’s Board of Directors has also approved a $2.0 billion increase in authorization for the company’s existing share repurchase plan. Based on these actions, the share repurchase plan has approximately $3.4 billion of repurchase authority available as of the date hereof to make repurchases pursuant to new or existing Rule 10b5-1 plans or otherwise.
Studies examine cancer-related malnutrition and nutrition management in pre-term babies, as well as the use of hemostats in specific pancreatic and spinal surgeries
Baxter International Inc. (BAX), a global leader in advancing surgical innovation, today unveiled the latest design enhancements for its fibrin sealant product, the Tisseel Prima syringe, at the 2018 American Association of Gynecologic Laparoscopists (AAGL) meeting. Attendees can visit Baxter’s booth #807 at the AAGL meeting this week for product demonstrations of the new Prima syringe and the Tisseel 40cm Duplotip Rigid Applicator, along with the rest of Baxter’s portfolio of hemostats and sealants that can be used during gynecological surgeries.
Baxter International Inc. , a leading global medical products company, will present at Citi’s 2018 Global Healthcare Conference on Thursday, December 6, 2018, in New York.
According to GuruFocus' list of 52-week lows, these Guru stocks have reached their 52-week lows. The price of International Business Machines Corp. (IBM) shares has declined to close to the 52-week low of $115.67, which is 33.3% off the 52-week high of $171.13. The company has a market cap of $105.12 billion.
In the daily bar chart of BAX, below, we can see a sharp decline in October that included a gap to the downside earlier this week. The slopes of both of these lagging indicators are negative or bearish. The daily On-Balance-Volume (OBV) line showed a positive trend until late September.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investing.com - Baxter (NYSE:BAX) reported third quarter earnings that beat analyst's expectations on Wednesday and revenue that fell short of forecasts.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Deerfield, Illinois-based company said it had net income of $1. Earnings, adjusted for non-recurring gains, were 80 cents per share. The results surpassed Wall Street expectations. ...